Prostatic tumor acid phosphatase production. Influence of antineoplastic agents.
D000135:Acid Phosphatase / Q000097:blood*; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D008926:Plicamycin / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D013852:Thiotepa / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001786:Blood Glucose; D003561:Cytarabine; D003609:Dactinomycin; D003520:Cyclophosphamide; D013852:Thiotepa; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D008926:Plicamycin; D005472:Fluorouracil; D008727:Methotrexate